Info

NOS: not otherwise specified.

aOnly 2 patients were followed for MRD.

NOS: not otherwise specified.

aOnly 2 patients were followed for MRD.

normal cells has been shown to predict outcome,24'26'28'29'31-35'39'40 while others were able to demonstrate prediction of outcome with more sensitive tests.12'25'27'30'34'36 These tests varied in their techniques' studying either tumor-specific DNA to detect residual malignant B cells by immunoglobulin gene rearrangement or residual malignant T cells by T-cell receptor genes,12'24-27'29'31'32'38'39 or tumor-specific RNA to detect fusion gene transcripts (e.gv BCR/ABLI TEL/AML1' MLL/AF4)36'40'42'43 or aberrantly expressed genes [e.gv FLT3 33'44 WT^28'30'35 HOX1133]. The tests also differed in the time points to analyze minimal residual disease' e.gv day 11 versus end of induction. Therefore' a molecular CR must incorporate the sensitivity of the test and timing' and also the gene analyzed to allow comparisons among different studies. Because of these issues' it is not possible to make a clear recommendation of how to use molecular testing to detect minimal residual disease outside of a correlative study to a clinical trial.

0 0

Post a comment